Permeation Enhancer‐based Ionogel Shows Remarkable Potential for Oral Insulin Delivery
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202500946 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Konstantinos Raptis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen, 2100, Denmark. Hauptthemen laut MEDLINE: Insulin, Drug Delivery Systems. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Lundbeck Foundation, Villum Fonden, Innovative Medicines Initiative Joint Undertaking.
Abstract (Originalsprache)
The increased focus on peptide therapeutics has created an unmet need for technologies and materials enabling therapeutic efficacy after oral administration. Currently, permeation enhancers are the gold standard for oral peptide delivery, with sodium decanoate being one of the most widely tested in preclinical and clinical studies. This study aims to develop and investigate a decanoate‐based ionic liquid (IL) inspired by the reported absorption enhancing effect of choline geranate (CAGE) IL. The delivery system is prepared by loading choline decanoate with insulin and upon optimization of the ratio, the chC 10 1:2 lead formulation shows gel‐like rheological properties. Its high viscosity and hydrophobicity results in slow dissolution in vitro and sustained absorption in vivo. In vivo data show that it can mediate a 7‐ and a 13‐fold higher oral bioavailability of insulin (6.5%) compared to CAGE (0.9%) and sodium decanoate (0.5%), respectively. Histological evaluation reveals that exposure to chC 10 1:2 does not affect villi morphology, while 15 min exposure to CAGE significantly reduces villi height. The villi erosion observed is transient and not significantly different from that observed with sodium decanoate. These results showcase the high potential of the chC 10 1:2 as an oral drug delivery vehicle.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen, 2100, Denmark.
- Center for Biopharmaceuticals and Biobarriers in Drug Delivery (BioDelivery), University of Copenhagen, Universitetsparken 2, Copenhagen, 2100, Denmark.
- Bioneer A/S, Kogle Allé 2, Hørsholm, 2970, Denmark.
- University of Copenhagen, LEO Foundation Center for Cutaneous Drug Delivery, Universitetsparken 2, Copenhagen, 2100, Denmark.
ORCID-Profile: Konstantinos Raptis, Joanne Heade, Cristiana Cunha, Marco van de Weert, Lasse Saaby, Stine Rønholt, Hanne Mørck Nielsen
Förderung
- Lundbeck Foundation
- Villum Fonden
- Innovative Medicines Initiative Joint Undertaking
- HORIZON EUROPE European Innovation Council
- Danmarks Grundforskningsfond
- Novo Nordisk Fonden
Zitieren
APA
Raptis, K., Heade, J., Cunha, C., van de Weert, M., Saaby, L., Rønholt, S., & Nielsen, H. M. (2025). Permeation Enhancer‐based Ionogel Shows Remarkable Potential for Oral Insulin Delivery. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202500946
Vancouver
Raptis K, Heade J, Cunha C, van de Weert M, Saaby L, Rønholt S, et al. Permeation Enhancer‐based Ionogel Shows Remarkable Potential for Oral Insulin Delivery. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202500946
BibTeX
@article{Raptis2025,
author = {Raptis, Konstantinos and Heade, Joanne and Cunha, Cristiana and van de Weert, Marco and Saaby, Lasse and Rønholt, Stine and Nielsen, Hanne Mørck},
title = {Permeation Enhancer‐based Ionogel Shows Remarkable Potential for Oral Insulin Delivery},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202500946}
}
EUVIMED